Industry › BioTech

Press Releases

OrbusNeich Announces First Annual Results After Listing, Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million

Mar 08, 2023 18:00 HKT/SGT

With U.S. Health Systems Under Growing Pressure to Fill Staff Vacancies, CGFNS Alliance Releases Updated Standards for Ethical Recruitment of Foreign Health Workers

Mar 07, 2023 13:30 HKT/SGT

随着美国卫生系统面临越来越大的填补人员空缺的压力，CGFNS 联盟发布了外国卫生工作者道德招聘的更新标准

Mar 07, 2023 13:30 HKT/SGT

隨著美國衛生系統面臨越來越大的填補人員空缺的壓力，CGFNS 聯盟發布了外國衛生工作者道德招聘的更新標準

Mar 07, 2023 13:30 HKT/SGT

医思健康香港自建旗舰宠物医院正式开幕

Mar 06, 2023 15:52 HKT/SGT

醫思健康香港自建旗艦寵物醫院正式開幕

Mar 06, 2023 15:51 HKT/SGT

EC Healthcare Opened the First Organic Flagship Veterinary Hospital in Hong Kong

Mar 06, 2023 15:50 HKT/SGT

エーザイ、「LEQEMBI」についてアルツハイマー病治療薬としてフル承認に向けた生物製剤承認一部変更申請（sBLA）が米国FDAに受理され、優先審査に指定

Mar 06, 2023 10:00 JST

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Mar 06, 2023 09:58 HKT/SGT

Prenetics宣布成立科學顧問委員會助力公司腫瘤精準醫療業務布局

Mar 04, 2023 15:41 HKT/SGT

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

Mar 04, 2023 15:40 HKT/SGT

CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022

Mar 03, 2023 08:00 HKT/SGT

バイオジェン・ジャパンとエーザイの日本における多発性硬化症治療剤の共同販促について

Mar 02, 2023 12:00 JST

Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan

Mar 02, 2023 09:45 HKT/SGT

Q&M reports lower full year profits due to impairments and decrease in Covid-19 related revenue

Mar 01, 2023 23:00 HKT/SGT

アリックスパートナーズ、日本市場でヘルスケア＆ライフサイエンス分野を拡大

Mar 01, 2023 10:00 JST

アリックスパートナーズ、日本市場でヘルスケア＆ライフサイエンス分野を拡大

Mar 01, 2023 10:00 JST

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

Feb 28, 2023 14:28 HKT/SGT

エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」の中国における生物ライセンス申請（BLA）が優先審査に指定

Feb 28, 2023 09:50 JST

Malaysian Genomics Pivots to Biopharmaceuticals for Growth

Feb 24, 2023 17:30 HKT/SGT